intervention models for these populations.

The research design will involve separate samples of African-Americans and Mexican-Americans between the ages of 40 and 64 with Type 2 Diabetes. Significant family members of these individuals will also participate. Participating families will be divided into two groups, an intervention group that will receive the intervention at the beginning of the study, and a comparison group that will receive a modified version at the end. Both self-report via questionnaires and more objective measures (e.g., hemoglobin blood glucose levels) of self-care adherence and diabetes control will be measured. Information collected will include diabetes knowledge, community characteristics, forms of social support, patient-provider relationship, and health care coverage. The total cost is estimated at $3,707.473.00

Respondents	No. of respondents	No. of responses/ respondent	Avg. burden of response (in hours)	Total burden (in hours)
Adult Diabetic and family member	800	6	6	28,800
Total				28,800

Dated: September 21, 1999.

Nancy Cheal,

Acting Associate Director for Policy, Planning and Evaluation Centers for Disease Control and Prevention (CDC).

[FR Doc. 99–25018 Filed 9–24–99; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administratiion for Children and Families

Proposed Information Collection Activity; Comment Request; Proposed Project

Title: Head Start Grant Application and Budget Instrument.

OMB No.: New.

Description: The Head Start program is promulgating a Head Start Grant Application and Budget Instrument to standardize the grant application information which is requested from all grantees applying for continuation grants. The Bureau is also instituting a three year grant funding cycle so that applicants will only submit full applications in their first year of their three year funding cycle. In addition, the Grant Application and Budget Instrument will be available on a data disk and can be transmitted electronically to Regional Offices. The Administration on Children, Youth and Families believes that, in promulgating this application document, the process of applying for grants for the Head Start program will be more efficient for the applicants.

Respondents: State, Local or Tribal Govt.

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
Head Start Grant Application and Budget Instrument	1,513	1	33	49,929

Estimated Total Annual Burden Hours: 49,929.

In compliance with the requirements of section 3506(c)(2)(A) the Paperwork Reduction Act of 1995, the Administration for Children and Families is soliciting public comment on the specific aspects of the information collection described above. Copies of the proposed collection of information can be obtained and comments may be forwarded by writing to the Administration for Children and Families, Office of Information Services, 370 L'Enfant Promenade, SW., Washington, DC. 20447, Attn: ACF Reports Clearance Officer. All requests should be identified by the title of the information collection.

The Department specifically requests comments on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Dated: September 21, 1999.

Bob Sargis,

Reports Clearance Officer.

[FR Doc. 99–24992 Filed 9–24–99; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Agency Recordkeeping/Reporting Requirements Under Emergency Review by the Office of Management and Budget (OMB)

Title: Head Start Grant Application and Budget Instrument.

OMB No.: New.

Description: The Head Start program is promulgating a Head Start Grant Application and Budget Instrument to standardize the grant application information which is requested from all grantees applying for continuation grants. The Bureau is also instituting a three year grant finding cycle so that applicants will only submit full applications in their first year of their

three year funding cycle. In addition, the Grant Application and Budget Instrument will be available on a data disk and can be transmitted electronically to Regional offices. The Administration on Children, Youth and Families believes that, in promulgating this application document, the process of applying for grants for the Head Start program will be more efficient for the applicants.

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
Head Start Grant Application and Budget Instrument	1,513	1	33	49,929

Estimated total Annual Burden Hours: 49,929.

Additional Information

ACF is requesting that OMB grant a 180 day approval for this information collection under procedures for emergency processing by October 25, 1999. A copy of this information collection, with applicable supporting documentation, maybe obtained by calling the Administration for Children and Families, Reports Clearance Officer, Bob Sargis at (202) 690–7275.

Comments and questions about the information collection described above should be directed to the following address by October 25, 1999: Office of Information and Regulatory Affairs, Attn: OMB Desk Officer for ACF, Office of Management and Budget, Paper Reduction Project, 725 17th Street, NW, Washington, DC 20503, (202) 395–7316.

Dated: September 21, 1999.

Bob Sargis,

Reports Clearance Officer.

[FR Doc. 99–24993 Filed 9–24–99; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Request for Nominations for Members on Public Advisory Panels or Committees; Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the establishment of the Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee (the Panel) in the Center for Devices and Radiological Health (CDRH). In this document, FDA is also requesting nominations for members to serve on the newly formed panel.

FDA has a special interest in ensuring that women, minority groups, and individuals with disabilities are adequately represented on advisory committees and, therefore, encourages nominations of qualified candidates from these groups. Final selection from among qualified candidates for each vacancy will be determined by the expertise required to meet specific agency needs and in a manner to ensure appropriate balance of membership.

DATES: Nominations should be received by October 27, 1999.

ADDRESSES: All nominations and curricula vitae, except for consumer-nominated and industry-nominated members, should be sent to Nancy J. Pluhowski (address below). All nominations and curricula vitae for the consumer-nominated members should be sent to Annette J. Funn (address below). All nominations for the industry-nominated members should be sent to Kathleen L. Walker (address below).

FOR FURTHER INFORMATION CONTACT:

Regarding all nominations for membership, except consumer-nominated and industry-nominated members: Nancy J. Pluhowski, Office of Device Evaluation (HFZ–400), CDRH, Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301–594–2022.

Regarding all nominations for consumer-nominated members: Annette J. Funn, Office of Consumer Affairs (HFE–88), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–5006.

Regarding all nominations for industry-nominated members: Kathleen L. Walker, Office of Systems and Management (HFZ–17), CDRH, Food and Drug Administration, 2098 Gaither Rd., Rockville, MD 20850, 301–594–1283, ext. 114.

SUPPLEMENTARY INFORMATION: The Panel was created on August 18, 1999. FDA is requesting nominations for members to serve on the new advisory panel. Persons nominated for membership should have expertise in the activity of the Panel as identified below.

Functions

The functions of the medical devices panels of the Medical Devices Advisory Committee are to: (1) Review and evaluate data on the safety and effectiveness of marketed and investigational devices and make recommendations for their regulation; (2) advise the Commissioner of Food and Drugs regarding recommended classification or reclassification of these devices into one of three regulatory categories; (3) advise on any possible risks to health associated with the use of devices; (4) advise on formulation of product development protocols; (5) review premarket approval applications for medical devices; (6) review guidelines and guidance documents; (7) recommend exemption to certain devices from the application of portions of the Federal Food, Drug, and Cosmetic Act (the act); (8) advise on the necessity to ban a device; (9) respond to requests from the agency to review and make recommendations on specific issues or problems concerning the safety and effectiveness of devices; and (10) make recommendations on the quality in the design of clinical studies regarding the safety and effectiveness of marketed and investigational devices.

Specifically, the function of the Molecular and Clinical Genetics Panel is to provide advice to the Commissioner on the appropriate scientific criteria to diagnostically test for human genes. In addition to the functions of the Medical Devices Advisory Committee, this panel shall review guidance and recommend criteria and classification of tests for human genes.

Criteria for Members

Persons nominated for membership on the Panel shall have expertise in human genetics and in the clinical management of patients with genetic disorders, e.g., pediatricians, obstetricians, and neonatologists. The agency is also interested in considering